Hepatic expression of the Sptlc3 subunit of serine palmitoyltransferase is associated with the development of hepatocellular carcinoma in a mouse model of nonalcoholic steatohepatitis

Oncology Reports

Volumn 33, Issue 4, 2015, Pages 1657-1666

  Yoshimine, Yozo ^a   Uto, Hirofumi ^a   Kumagai, Kotaro ^a   Mawatari, Seiichi ^a   Arima, Shiho ^a   Ibusuki, Rie ^a   Mera, Kumiko ^a   Nosaki, Tsuyoshi ^a   Kanmura, Shuji ^a   Numata, Masatsugu ^a   Tamai, Tsutomu ^a   Moriuchi, Akihiro ^a   Tsubouchi, Hirohito ^a,b   Ido, Akio ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b K   (Japan)

Author keywords

Cxcl14; Grip1; Insulin secretion; Mmp13; Nonalcoholic steatohepatitis; Sptlc3

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; COMPLEMENTARY DNA; MESSENGER RNA; SERINE PALMITOYLTRANSFERASE; ASPARTATE AMINOTRANSFERASE; LEPTIN RECEPTOR; LEPTIN RECEPTOR, MOUSE; SPTLC3 PROTEIN, MOUSE; STREPTOZOCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MALE; MICROARRAY ANALYSIS; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; SPTLC3 GENE; ADVERSE EFFECTS; ANIMAL; BIOSYNTHESIS; BLOOD; C57BL MOUSE; COCARCINOGENESIS; COMPARATIVE STUDY; COMPLICATION; DEFICIENCY; DISEASE COURSE; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; GENE EXPRESSION PROFILING; GENETICS; HYPERGLYCEMIA; HYPERINSULINISM; LIPID DIET; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; PATHOLOGY; PRECANCER; VITAMIN DEFICIENCY;

ALANINE TRANSAMINASE; ALPHA-FETOPROTEINS; ANIMALS; ASPARTATE AMINOTRANSFERASES; CHOLINE DEFICIENCY; COCARCINOGENESIS; DIABETES MELLITUS, EXPERIMENTAL; DIET, HIGH-FAT; DISEASE PROGRESSION; GENE EXPRESSION PROFILING; HYPERGLYCEMIA; HYPERINSULINISM; LIVER; LIVER CIRRHOSIS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED C57BL; NON-ALCOHOLIC FATTY LIVER DISEASE; PRECANCEROUS CONDITIONS; RECEPTORS, LEPTIN; RNA, MESSENGER; SERINE C-PALMITOYLTRANSFERASE; STREPTOZOCIN;

EID: 84924912275     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3745     Document Type: Article

References (35)

1. Ludwig J, Viggiano TR, McGill DB and Oh BJ: Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55: 434-438, 1980.
2. Andy SY and Keeffe EB: Nonalcoholic fatty liver disease. Rev Gastrointest Disord 2: 11-19, 2002.
3. Angulo P and Lindor KD: Non-alcoholic fatty liver disease Quadrennial review. J Gastroenterol Hepatol 17: S186-S190, 2002.
4. W hite DL, Kanwal F and El-Serag HB: Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 10: 1342-1359, 2012.
5. Ikai I, Arii S, Okazaki M, Okita K, Omata M, Kojiro M, Takayasu K, Nakanuma Y, Makuuchi M, Matsuyama Y, Monden M and Kudo M: Report of the 17th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 37: 676-691, 2007.
6. Day CP and James OF: Steatohepatitis: a tale of two 'hits'? Gastroenterology 114: 842-845, 1998.
7. Tilg H and Moschen AR: Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846, 2010.
8. Anstee QM and Goldin RD: Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16, 2006.
9. Denda A, Kitayama W, Kishida H, Murata N, Tsutsumi M, Tsujiuchi T, Nakae D and Konishi Y: Development of hepatocellular adenomas and carcinomas associated with fibrosis in C57BL/6J male mice given a choline-deficient, L-amino aciddefined diet. Jpn J Cancer Res 93: 125-132, 2002.
10. Fujii M, Shibazaki Y, Wakamatsu K, Honda Y, Kawauchi Y, Suzuki K, Arumugam S, Watanabe K, Ichida T, Asakura H and Yoneyama H: A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma. Med Mol Morphol 46: 141-152, 2013.
11. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, Mccullough AJ, Sanyal AJ and Nonalcoholic Steatohepatitis Clinical Research N: Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321, 2005.
12. Renehan A, Smith U and Kirkman MS: Linking diabetes and cancer: a consensus on complexity. Lancet 375: 2201-2202, 2010.
13. Rosmorduc O and Fartoux L: HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 36: 202-208, 2012.
14. Shimizu M, Tanaka T and Moriwaki H: Obesity and hepatocellular carcinoma: targeting obesity-related inflammation for chemoprevention of liver carcinogenesis. Semin Immunopathol 35: 191-202, 2013.
15. Morss AS and Edelman ER: Glucose modulates basement membrane fibroblast growth factor-2 via alterations in endothelial cell permeability. J Biol Chem 282: 14635-14644, 2007.
16. Niwa Y, Matsumura M, Shiratori Y, Imamura M, Kato N, Shiina S, Okudaira T, Ikeda Y, Inoue T and Omata M: Quantitation of alpha-fetoprotein and albumin messenger RNA in human hepatocellular carcinoma. Hepatology 23: 1384-1392, 1996.
17. Yao M, Yao DF, Bian YZ, Wu W, Yan XD, Yu DD, Qiu LW, Yang JL, Zhang HJ, Sai WL and Chen J: Values of circulating GPC-3 mRNA and alpha-fetoprotein in detecting patients with hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 12: 171-179, 2013.
18. Satoh K, Takahashi G, Miura T, Hayakari M and Hatayama I: Enzymatic detection of precursor cell populations of preneoplastic foci positive for gamma-glutamyltranspeptidase in rat liver. Int J Cancer 115: 711-716, 2005.
19. Shin E, Ryu HS, Kim SH, Jung H, Jang JJ and Lee K: The clinicopathological significance of heat shock protein 70 and glutamine synthetase expression in hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 18: 544-550, 2011.
20. Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P and Belghiti J: Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology 49: 851-859, 2009.
21. W en H, Gris D, Lei Y, Jha S, Zhang L, Huang MT, Brickey WJ and Ting JP: Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling. Nat Immunol 12: 408-415, 2011.
22. Hanada K: Serine palmitoyltransferase, a key enzyme of sphingolipid metabolism. Biochim Biophys Acta 1632: 16-30, 2003.
23. Menaldino DS, Bushnev A, Sun A, Liotta DC, Symolon H, Desai K, Dillehay DL, Peng Q, Wang E, Allegood J, Trotman?Pruett S, Sullards MC and Merrill AH Jr.: Sphingoid bases and de novo ceramide synthesis: enzymes involved, pharmacology and mechanisms of action. Pharmacol Res 47: 373-381, 2003.
24. Hornemann T, Richard S, Rütti MF, Wei Y and Von E ckardstein A: Cloning and initial characterization of a new subunit for mammalian serine-palmitoyltransferase. J Biol Chem 281: 37275-37281, 2006.
25. Hornemann T, Wei Y and Von Eckardstein A: Is the mammalian serine palmitoyltransferase a high-molecular-mass complex? Biochem J 405: 157-164, 2007.
26. Cinar R, Godlewski G, Liu J, Tam J, Jourdan T, Mukhopadhya B, Harvey-White J and Kunos G: Hepatic cannabinoid-1 receptors mediate diet-induced insulin resistance by increasing de novo synthesis of long-chain ceramides. Hepatology 59: 143-153, 2014.
27. U ssher JR, Koves TR, Cadete VJ, Zhang L, Jaswal JS, Swyrd SJ, Lopaschuk DG, Proctor SD, Keung W, Muoio DM and Lopaschuk G D: Inhibition of de novo ceramide synthesis reverses diet-induced insulin resistance and enhances whole-body oxygen consumption. Diabetes 59: 2453-2464, 2010.
28. Lyn-Cook LE Jr., Lawton M, Tong M, Silbermann E, Longato L, Jiao P, Mark P, Wands JR, Xu H and de La Monte SM: Hepatic ceramide may mediate brain insulin resistance and neurodegeneration in type 2 diabetes and non-alcoholic steatohepatitis. J Alzheimers Dis 16: 715-729, 2009.
29. Promrat K, Longato L, Wands JR and De La Monte SM: Weight loss amelioration of non-alcoholic steatohepatitis linked to shifts in hepatic ceramide expression and serum ceramide levels. Hepatol Res 41: 754-762, 2011.
30. Kurek K, Wiesiolek-Kurek P, Piotrowska DM, Lukaszuk B, Chabowski A and Zendzianendzian-Piotrowska M: Inhibition of ceramide de novo synthesis with myriocin affects lipid metabolism in the liver of rats with streptozotocin-induced type 1 diabetes. Biomed Res Int 2014: 980815, 2014.
31. Lee YS, Choi KM, Choi MH, Ji SY, Lee S, Sin DM, Oh KW, Lee YM, Hong JT, Yun YP and Yoo HS: Serine palmitoyltransferase inhibitor myriocin induces growth inhibition of B16F10 melanoma cells through G(2)/M phase arrest. Cell Prolif 44: 320-329, 2011.
32. Lee YS, Choi KM, Lee S, Sin DM, Lim Y, Lee YM, Hong JT, Yun YP and Yoo HS: Myriocin, a serine palmitoyltransferase inhibitor, suppresses tumor growth in a murine melanoma model by inhibiting de novo sphingolipid synthesis. Cancer Biol Ther 13: 92-100, 2012.
33. G reenbaum CJ: Insulin resistance in type 1 diabetes. Diab Metab Res Rev 18: 192-200, 2002.
34. Bulum T, Kolaric B, Duvnjak L and Duvnjak M: Nonalcoholic fatty liver disease markers are associated with insulin resistance in type 1 diabetes. Dig Dis Sci 56: 3655-3663, 2011.
35. Regnell SE and Lernmark A: Hepatic steatosis in type 1 diabetes. Rev Diab Stud 8: 454-467, 2011.